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NNPPV influences respiratory muscle capacity and walking distance
Background/Purpose: This study was designed to investigate the effects of 6 months of nocturnal nasal positive
pressure ventilation (NNPPV) on respiratory muscle function and exercise capacity in patients with chronic
respiratory failure.
Methods: A prospective, randomized, controlled design was used. Twenty-nine patients with chronic respiratory
failure were enrolled and allocated to either the NNPPV (n = 14) or control group (n = 15). Patients in the
NNPPV group received bi-level positive pressure ventilation via nasal mask for 6 consecutive months. Arterial
blood gas, respiratory muscle assessment and 6-minute walk test (6MWT) were performed before and after
the 6-month NNPPV intervention. Respiratory muscle function was assessed using the variables of maximal
inspiratory pressure (Pimax), maximal expiratory pressure (Pemax), and maximum voluntary ventilation
(MVV).
Results: Subjects in the NNPPV group showed a significant improvement in blood gas exchange and increased
6-minute walk distance (6MWD) compared to baseline and the control group. The 6MWD was significantly
increased from 257.1 ± 114.1 to 345.2 ± 109.9 m (34.3%) in the NNPPV group. NNPPV also significantly
improved MVV and Pimax relative to baseline. MVV was significantly increased from 19.2 ± 6.5 to 22.3 ± 7.1
L/min (16.1%) in the NNPPV group (p < 0.05). Furthermore, there was a significant correlation between the
magnitude of MVV improvement and 6MWD change.
Conclusion: The 6-month NNPPV treatment significantly decreased the partial pressure of carbon dioxide
and improved daytime respiratory muscle function, thus contributing to exercise-capacity increase in patients
with chronic respiratory failure. [J Formos Med Assoc 2006;105(6):459–467]
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Noninvasive positive pressure ventilation (NPPV)
is effective for the treatment of chronic respiratory
failure in patients with restrictive ventilatory dis-
orders, particularly those with neuromuscular dis-
ease and kyphoscoliosis.1,2 In most reports, long-
term intermittent NPPV was implemented during
sleep to avoid interruption of daytime activities,
as well as to attenuate sleep-related breathing dis-
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turbances in patients with significant underlying
respiratory disorders.3,4 There is limited quanti-
tative data on the physiologic effects of NPPV in
patients with severe hypercapnic respiratory fail-
ure. In addition, conflicting results have been
reported with respect to its efficacy for improving
gas exchange, respiratory mechanics and exercise
capability.
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graphy study;8 (3) medically stable; and (4) well
motivated. Exclusion criteria were: (1) diagnosis
of moderate to severe obstructive sleep apnea,
i.e. apnea hypopnea index (AHI) > 20 events/
hour;14 (2) unable to complete the 6-minute
walk test (6MWT); (3) unable to tolerate NNPPV
or failure to cooperate; and (4) participation in
an exercise rehabilitation program. All enrolled
patients were assigned a computer-generated ran-
dom number.
Subjects in the NNPPV group were asked to
use bi-level positive pressure (BiPAP) ventilation
via nasal mask for at least 6 hours during sleep
for 6 consecutive months. The study protocol was
approved by the Ethical Review Committee at
Chung Gung Memorial Hospital, and informed
consent was obtained from all patients prior to
study enrollment.
Interventions
Nocturnal ventilation was delivered using the
BiPAP system (Respironics Inc, Murrysville, PA,
USA) via nasal mask (Respironics Inc). All patients
were admitted to the thoracic ward to adjust the
inspiratory positive airway pressure (IPAP) and
the expiratory positive airway pressure (EPAP).
Initially, IPAP was set at 2 cmH2O and EPAP was
set at 2 cmH2O. IPAP was then increased to 8, 12,
16 and 20 cmH2O and EPAP was then increased to
4, 6 and 8 cmH2O. Inspiratory and expiratory
pressures were set to achieve daytime PaCO2 <
45mmHg and PaO2 > 60 mmHg or oxygen satura-
tion (O2SAT) > 88%. Supplemental oxygen was
added to maintain O2SAT * 88% during NNPPV.
Subjects in the NNPPV group were instructed to
use nasal ventilation at night during sleep. Com-
pliance with the NNPPV treatment regimen was
evaluated by reviewing the subjects’ log records
and the machine meter. Subjects were followed up
monthly at our clinic. Five patients in the NNPPV
group withdrew from the study due to intolerance
of BiPAP.
Measurements
Patients in the NNPPV group were asked to stop
using bronchodilators for 12 hours and then
It has been demonstrated that short-term
NPPV markedly improves sleep efficiency and to-
tal sleep time in patients with hypercapnic chro-
nic obstructive pulmonary disease (COPD) with-
out significantly improving gas exchange.5 The
long-term nightly use of noninvasive mechani-
cal ventilation (NIMV) to treat chronic respiratory
failure in COPD patients, however, is not widely
recommended, partly because of the lack of clear
clinical results, and partly because the physiologic
mechanisms by which the daily application of
NIMV would be helpful in these patients have not
yet been clarified.6
The exercise capacity of patients with chronic
ventilatory failure is markedly reduced.7 It appears
reasonable to suggest that daytime respiratory
muscle dysfunction may contribute to exercise im-
pairment. Accessory muscle and diaphragmatic
electromyographic activity may be reduced by
both negative8 and positive9 ventilation in patients
with chronic respiratory failure. It could be hypo-
thesized, therefore, that the reduction in energy
expenditure at night could result in improved
respiratory muscle function during the day. Al-
though many studies have explored the effects
of nocturnal nasal positive pressure ventilation
(NNPPV) on respiratory muscle function, the
benefits proposed for long-term NNPPV, in terms
of exercise performance, remain controversial.10–12
We investigated the effects of a 6-month course
of NNPPV treatment on arterial blood gas tension,
respiratory muscle function, and exercise capacity
in a prospective, randomized controlled trial in
patients with chronic respiratory failure.
Methods
Subjects
Patients with chronic hypercapnic respiratory
failure were recruited from the outpatient clinic of
Chung Gung Memorial Hospital. The inclusion
criteria were: (1) daytime PaCO2 > 45 mmHg, pH
7.30–7.45;13 (2) pulse oxygen saturation (SpO2)
< 88% for more than 5 consecutive minutes on
room air during sleep according to polysomno-
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breathed room air for 4 hours before tests. Base-
line data were measured before subjects began the
study treatment. These included arterial blood gas
tension, respiratory muscle function, and 6-minute
walk distance (6MWD). All measurements were
then repeated at the end of the 6-month treatment.
Arterial blood samples were collected on room air.
A Corning 278 blood gas analyzer (Ciba-Corning
Diagnostics Co, Walpole, MA, USA) was used to
perform arterial blood gas analysis. Maximum vol-
untary ventilation (MVV) was measured by a port-
able spirometer (Spiro Analyzer ST 250; Fukuda,
Sangyo, Japan) in accordance with the recommen-
dations of the American Thoracic Society.15 The 12-
second MVV was also measured. Mouth occlusion
pressures at maximum inspiratory pressure (Pimax)
and maximum expiratory pressure (Pemax) were
measured using a plethysmograph pulmonary
function test system (Erich Jaeger, Hoechberg,
Germany). Pimax was measured at residual vol-
ume (RV) and Pemax was measured at total lung
capacity (TLC) with the subject seated in a hard-
backed chair. As soon as the patient commenced
inhalation, the shutter closed and the pressure was
measured automatically. These procedures were
repeated until three measurements with less than
5% variability were recorded, with the highest of
these utilized for analysis.
Exercise capacity was measured by 6MWT16
before and after 6 months of treatment. In order
to exclude the learning effect, all patients were
asked to complete a practice session of 6MWT 1
week before enrollment in the study. Subjects were
encouraged every 30 seconds using one of the two
phrases, “You are doing well” and “Keep up the
good work”. Subjects were allowed to stop and rest
during the test, but were instructed to resume walk-
ing as soon as they felt able to do so. The longest
of the two walk distances was used in the analysis.
The test was performed without oxygen supple-
mentation. Modified Borg scales were evaluated at
rest and immediately after exercise, and expressed
as RBorg and ExBorg, respectively.17 Subjects were
connected to a pulse oximeter (3301; BCI Interna-
tional Co, Waukesha, WI, USA) for monitoring of
O2SAT. O2SAT was recorded and printed out every
6 seconds at rest and during exercise. Both resting
oxygen saturation (RO2SAT) and exercise oxygen
saturation (ExO2SAT) were determined by the pulse
oximeter.
Statistical analysis
SPSS version 10.0 software (SPSS Inc, Chicago, IL,
USA) was used for statistical analysis. The results
are presented as mean ± SD. The Wilcoxon signed
rank test was used to determine within-group dif-
ferences before and after treatment. The Mann-
Whitney rank sum test was used to assess the dif-
ference between groups, with the Spearman rank
correlation coefficient used to examine the rela-
tionship between the changes in walking distance
and respiratory muscle function. A p value of less
than 0.05 was considered to be statistically signifi-
cant for all tests.
Results
A total of 37 patients were enrolled and allocated
randomly to either the control (standard treatment;
n = 18) or the NNPPV groups (standard treatment
plus NNPPV; n = 19) during the period from June
2001 through July 2003, inclusively. Four subjects
in the NNPPV group were unable to tolerate the
treatment within 3 months of commencement and
were excluded from the data analysis. One patient
in the NNPPV group and three controls died dur-
ing the 6-month intervention period, leaving re-
spective patient completion totals of 14 and 15.
No significant between-group differences were
found on comparing age, gender distribution, body
mass and AHI, disease character, and home oxy-
gen usage (Table 1).
For the NNPPV group, peak inspiratory pres-
sure was 15.8 ± 0.6 cmH2O, and positive expira-
tory pressure was 4.5 ± 0.4 cmH2O. Treatment com-
pliance was confirmed by duration of use as re-
corded by the ventilator. The mean nightly duration
of use was 6.8 ± 0.6 hours. There was a strong cor-
relation between patient and machine records (r =
0.88), with the former exceeding the latter by about
12%.
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Arterial blood gas tension at baseline and after
completion of the 6-month study are shown in
Table 2. There were no significant between-group
differences comparing the baseline data for pH,
PaO2, PaCO2, and HCO3
–. NNPPV therapy showed
a significant improvement in daytime blood gas
parameters, with a significant increase in PaO2
(p = 0.013) and a significant decrease in PaCO2,
HCO3
– and BE (p = 0.001, p = 0.001 and p = 0.002,
respectively). Further, the magnitudes of the PaCO2
and HCO3
– decreases were more significant for the
NNPPV group than for the controls.
At the end of the 6-month treatment period,
MVV was significantly improved in the NNPPV
group (from 19.16 ± 6.45 to 22.33 ± 7.11 L/min;
p < 0.05, n = 14), but not in the control group
(from 18.07 ± 5.68 to 17.04 ± 6.17 L/min; p >
0.05, n = 15) (Figure 1). Further, Pimax was signi-
ficantly increased in the NNPPV group (from
4.00 ± 1.44 to 4.83 ± 1.88 Kpa; p < 0.05, n = 14)
but not in the controls (from 4.68 ± 1.79 to 4.47 ±
2.03 Kpa; p > 0.05, n = 15) (Figure 2). In this study,
6-month NNPPV therapy resulted in mean in-
creases of 16.7% and 20.8% from baseline for
Table 1. Demographic, clinical and respiratory related characteristics of patients in the control and
nocturnal nasal positive pressure ventilation (NNPPV) groups
Control (n = 15) NNPPV (n = 14) p
Age (yr) 65.6 ± 10.0 58.9 ± 12.7 0.1904
Gender (M:F) 11:4 8:6 0.3590
Weight (kg) 54.5 ± 12.8 50.1 ± 14.1 0.3049
Height (cm) 155.2 ± 9.700 151.4 ± 12.40 0.4712
BMI (kg/m2) 22.6 ± 5.50 21.2 ± 4.30 0.6625
Parameters during sleep study
Desaturation, minimum O2SAT (%) 71.1 ± 10.9 71.1 ± 11.3 0.9478
ODI (%) 23.3 ± 28.0 17.7 ± 20.3 0.8613
AHI (%) 9.6 ± 7.0 9.0 ± 9.2 0.4321
Patients using oxygen at home, n (%) 8 (53.3) 7 (50.0) 0.5730
Diagnosis related to respiratory function, n (%)
COPD 11 (73.3)0 10 (71.4)0
Pneumoconiosis 2 (13.3) 1 (7.1)0 0.7610
Scoliosis 2 (13.3) 3 (21.4)
Baseline ABG analysis
pH 7.41 ± 0.07 7.40 ± 0.05 0.7328
PaO2 (mmHg) 57.85 ± 9.400 54.31 ± 9.010 0.3114
PaCO2 (mmHg) 52.65 ± 4.020 56.26 ± 7.780 0.1237
HCO3
– (mmol/L) 33.41 ± 4.010 34.95 ± 5.580 0.3974
Borg scale
RBorg 2.7 ± 0.9 3.2 ± 1.5 0.2928
ExBorg 5.8 ± 1.2 5.8 ± 1.5 0.9774
Respiratory parameters
Pimax (Kpa) 4.68 ± 1.79 4.00 ± 1.44 0.2738
Pemax (Kpa) 7.40 ± 2.27 6.11 ± 1.48 0.0846
MVV (L/min) 18.07 ± 5.680 19.16 ± 6.450 0.6370
BMI = body mass index; O2SAT = oxygen saturation; ODI = oxygen desaturation index (frequency of 4% < baseline per hour);
AHI = apnea hypopnea index (events per hour); COPD = chronic obstructive pulmonary disease; ABG = arterial blood gas;
PaO2 = partial pressure of arterial oxygen; PaCO2 = partial pressure of arterial carbon dioxide; HCO3
– = arterial bicarbonate;
RBorg = resting Borg score; ExBorg = Borg score at the end of the 6-minute walk test; Pimax = maximal inspiratory pressure;
Pemax = maximal expiratory pressure; MVV = maximum voluntary ventilation.
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MVV and Pimax, respectively. As shown in Figure
3, however, there were no significant differences
in Pemax for either group (from 6.11 ± 1.48 to
6.87 ± 1.92 Kpa and from 7.40 ± 2.27 to 6.76 ±
2.17 Kpa for the NNPPV and control groups, re-
spectively; p > 0.05). As shown in Figure 4, a signi-
ficant correlation was found between improved
Pimax and increased MVV (rs = 0.56, p < 0.05; n =
14). No significant differences were found between
baseline data for MVV, Pimax and Pemax between
the NNPPV and control groups.
As shown in Figure 5, NNPPV treatment also
resulted in a significant improvement in 6MWD
compared to baseline (from 257.1 ± 114.1 to
345.2 ± 109.9 m; p < 0.001), whereas this value
was significantly decreased in the control group
(from 291.7 ± 96.0 to 258.8 ± 97.7; p < 0.001).
The mean increase from baseline was 88.1 m
(34.3%) for the NNPPV group, and the mean re-
duction was 32.9 m (–11.3%) for the control group
(p < 0.05; Figure 5). As shown in Figure 6, the
change in 6MWD in the NNPPV group was signi-
ficantly correlated with increased MVV (rs = 0.77,
p < 0.01; n = 14) for the NNPPV group.
Compared to baseline, NNPPV patients also
achieved significant reductions in resting dyspnea
sensation (RBorg) and improved RO2SAT; how-
ever, no such significance was achieved for the con-
trol group (Table 3).
Discussion
This study demonstrated that 6 months of NNPPV
treatment was effective in improving arterial blood
gas tension and 6MWD in patients with chronic
respiratory failure. NNPPV was also associated with
Table 2. Arterial blood gases at baseline and after 6 months in the control and nocturnal nasal
positive pressure ventilation (NNPPV) groups
Control (n = 15) NNPPV (n = 14)
Baseline After treatment Baseline After treatment
pH 7.41 ± 0.07 7.39 ± 0.06 7.40 ± 0.05 7.40 ± 0.03
(7.32–7.48) (7.30–7.49) (7.33–7.50) (7.34–7.44)
PaO2 (mmHg) 57.85 ± 9.40 61.69 ± 9.29 54.31 ± 9.01 58.79 ± 11.61*
(42.8–72.50) (50.10–75.90) (39.60–68.00) (39.00–80.60)
PaCO2 (mmHg) 52.65 ± 4.02 53.18 ± 13.10 56.26 ± 7.78 44.59 ± 6.02
†‡
(46.80–60.30) (39.70–93.00) (46.90–69.30) (35.00–55.70)
HCO3
– (mmol/L) 33.41 ± 4.01 32.01 ± 5.78 34.95 ± 5.58 28.59 ± 5.53†‡
(26.30–41.60) (22.60–46.00) (28.00–49.20) (22.40–45.10)
BE (mmol/L) 7.75 ± 4.48 6.16 ± 4.41 8.72 ± 5.24 3.73 ± 4.54§
(–3.00–16.90) (–1–15.90) (2.90–22.00) (–0.9–17.00)
O2SAT (%) 88.38 ± 5.38 89.95 ± 4.66 85.82 ± 7.23 88.35 ± 7.14*
(79.5–95.3) (78.3–95.3) (70.40–93.40) (71.40–96.10)
*p < 0.05 vs. baseline; †p < 0.001 vs. baseline; ‡p < 0.05 vs. control group; §p < 0.01 vs. baseline. PaO2 = partial pressure of arterial
oxygen; PaCO2 = partial pressure of arterial carbon dioxide; HCO3
– = arterial bicarbonate; BE = base excess; O2SAT = oxygen saturation.
Figure 1. Maximum voluntary ventilation (MVV) was significantly improved for the
nocturnal nasal positive pressure ventilation (NNPPV) group (n = 14), but not for the
control group (n = 15).
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improvements in respiratory muscle capacity
(including Pimax and MVV), which may have also
contributed to the increase in daytime exercise
endurance.
While several previous studies suggested that
NNPPV may improve arterial blood gas tension in
chronic respiratory failure patients, these studies
lacked a randomized controlled design and the
treatment period ranged from 3 to 6 months.3,4,18,19
Conversely, Krachman et al concluded that, despite
improved sleep efficiency and total sleep time,
short-term NPPV does not alter gas exchange in
patients with hypercapnic COPD.5 Our study dem-
onstrated that 6-month NNPPV is effective for im-
proving alveolar ventilation in chronic respiratory
failure patients. The increased level of ventilation
may result in a resetting of the central respiratory
chemoreceptors that lead to a reduction in day-
time PaCO2.
20,21
The benefits of NNPPV with respect to respira-
tory muscle function remain controversial. Some
studies of respiratory muscle function have failed
to confirm improvement in Pimax and Pemax
after NNPPV treatment in chronic respiratory fail-
ure patients,3,17 especially for specific diagnostic
subgroups such as severe COPD22 and severe cys-
tic fibrosis.23 However, Piper et al found that
NNPPV improved Pimax in patients with cystic
fibrosis and hypercapnic respiratory failure.24
Moreover, Schonhofer et al11 and Goldstein et al12
reported beneficial effects of NNPPV on inspira-
tory threshold-loading test in patients with restric-
tive lung diseases. Similarly, Cropp and Dimarco
found that nocturnal ventilation increased day-
time respiratory muscle endurance in patients with
severe COPD based on the measurements of the
maximum duration of 12-second MVV.10 It could
be speculated, therefore, that the major benefits
of NNPPV are enhancement of rest in chronically
fatigued inspiratory muscles and improved alveo-
lar ventilation and exercise tolerance. This study
demonstrated that NNPPV treatment is not only
associated with a significant increase in Pimax,
but that it also improves MVV, which influences
muscle strength and endurance. We also found that
the Pimax increase was associated with improve-
ment in MVV, suggesting that the major effects of
NNPPV on maximum voluntary alveolar ventila-
tion may be through influence on respiratory mus-
cle capacity.
Figure 2. Maximal inspiratory pressure (Pimax) was significantly improved for
the nocturnal nasal positive pressure ventilation (NNPPV) group (n = 14), but not for
the control group (n = 15).
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Figure 3. There were no significant differences in maximal expiratory pressure
(Pemax) in either group.
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Figure 4. Correlation between changes in maximum voluntary
ventilation (MVV) and maximal inspiratory pressure (Pimax) (rs =
0.56, p < 0.05; n = 14).
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Patients with severe COPD often have intrinsic
positive end-expiratory pressure (PEEPi), which
requires that inspiratory muscles overcome an op-
posing positive-recoil pressure before inspiratory
airflow begins.25 The expiratory positive airway
pressure settings used in NNPPV treatment in our
patients may have partially compensated for the
PEEPi, thus reducing the inspiratory threshold
load needed to trigger the IPAP boost. This may
decrease inspiratory muscle work and central drive.
A decrease in inspiratory threshold load also al-
lows a triggered IPAP-related increase in tidal vol-
ume (VT). This may partially explain the observed
NNPPV-related improvements in Pimax and MVV
in our chronic respiratory failure patients. How-
ever, the lack of use of an endoesophageal balloon
to measure the effects of NPPV on inspiratory mus-
cle effort, which would have also enabled us to
measure PEEPi and the effects of NPPV on EELV,
is an important study limitation.
In recent years, there has been increasing inte-
rest in the use of NPPV to increase exercise capa-
city in chronic respiratory failure patients. Patho-
physiologic factors known to contribute to exer-
cise limitations in chronic respiratory failure pa-
tients include increased intrinsic mechanical load-
ing of inspiratory muscles (i.e. PEEPi), inspiratory
threshold load,26 increased mechanical restriction
of the thorax, inspiratory muscle weakness, in-
creased ventilatory demand relative to capacity, gas-
exchange abnormalities, dynamic airway compres-
sion, cardiovascular factors, or any combination
of the above.27 Gains in muscle mass and strength
have been associated with improved exercise tol-
erance and survival.28 In this study, we found that
NNPPV therapy for 6 months was associated with
significantly increased 6MWD. We also demon-
strated that NNPPV improved gas exchange, Pimax
and MVV, which may have also contributed to im-
provements in 6MWD. These findings suggest
that the mechanisms responsible for the effects
of NNPPV on exercise endurance are complex and
their delineation will require further investigation.
A sensation of breathlessness is the most com-
mon symptom limiting exercise, with alleviation
of breathlessness seemingly important for improv-
Figure 5. Relative to baseline, nocturnal nasal positive pressure ventilation (NNPPV)
resulted in a significant improvement in 6-minute walk distance (6MWD), whereas this
value was significantly decreased in the control group.
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ing exercise endurance.29,30 This study showed
that NNPPV not only significantly decreased the
sensation of breathlessness (RBorg; Table 3),
but it also increased RO2Sat (Table 3) and Pimax
(Figure 2). Thus, the reduction in breathlessness
in our study may have been due to an improve-
ment in gas exchange.
The changes in exercise endurance may also
be associated with the various support modalities
and/or treatment periods. In a recent study, it was
found that 2-month NNPPV significantly improved
6MWD in patients with chronic respiratory fail-
ure (by approximately 18%), but did not improve
quadriceps strength.31 In our investigation, 6
months of NNPPV therapy was associated with
a significant increase in 6MWD (88.1 m, 34.3%),
a finding superior to that reported by Schonhofer
et al.31 This suggests that long-term treatment may
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Figure 6. Correlation between changes in maximum voluntary
ventilation (MVV) and 6-minute walking distance (6MWD) (rs =
0.77, p < 0.01; n = 14).
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be important for improved exercise endurance.
The effects of the 6-month therapy on quadriceps
strength remain unclear. Further, the mean level
of improvement in 6MWD in our study was com-
parable to that achieved after a 6-week outpatient
exercise training program for COPD patients,32 and
superior to an inpatient rehabilitation program for
severe but stable COPD patients,33 suggesting that
improvements in exercise tolerance and quality of
life can be achieved and sustained for 6 months in
patients undergoing NNPPV compared with those
receiving conventional care.
Four of the NNPPV patients withdrew from the
study within 3 months because they could not tole-
rate BiPAP during sleep. The dropout rate in our
study (21.1%; 4/19) was similar to that reported
by Gay et al (19%),3 but less than that described
by Criner et al (28%). 18 The major causes for drop-
out in our study included mask leak, discomfort
arising from the headwear, nasal bridge pres-
sure and eye irritation. The comfort and compli-
ance of patients may have been improved through
recruitment of a home care company to apply tech-
nological readjustment, personal reassurance and
education.
Other limitations of our study also need to be
mentioned. Ideally, the effects of NNPPV on res-
piratory muscle endurance performance should
be examined using the pressure threshold-loading
test. As clinical facilities for such testing were not
available, however, the MVV was measured as an
alternative. Further, patients with neuromuscular
disorders were excluded from this investigation
because they were not able to complete the 6MWT.
We conclude that, for our sample of chronic
respiratory failure patients, 6-month NNPPV ther-
apy improved arterial blood gas and exercise ca-
pacity compared to the control group. Further,
NNPPV therapy was also associated with increased
Pimax and MVV, which may have contributed to
the increased exercise capacity in these patients.
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